Together with our World-class partners, we are bringing life-changing phage therapies to the market



The Weizmann Institute of Science:
BiomX has exclusively licensed two underlying technologies that have been developed in the labs of Prof. Rotem Sorek and Prof. Eran Elinav at the Weizmann Institute of Science, Israel.

The licensed technologies include:
1. Access to phage discovery systems as the basis of the Microbiome Modulation platform, as well as in-vitro and in-vivo validation capabilities.

2. Access to the target bacteria discovery platform for identification of target bacteria and bacteria genes of complex microbiomes.

In collaboration with Takeda, BiomX is developing formulations for its phage therapy manufacturing intermediates and for the final form to be administered. The intermediate drug formulation enables long term storage and shipping under conditions that are cost efficient with virtually no loss in phage activity over extended periods of time. Co-operation on the formulations for administration have indicated that these industry standard alternatives for phage delivery support minimal losses in phage activity when phage are introduced into them.

JSR Corporation:
BiomX has exclusively sub-licensed from JSR Corporation a set of bacterial targets for the development and commercialization of phage therapies that eradicate these targets, as a treatment for IBD. These targets, discovered by Dr. Kenya Honda, Professor of Microbiology and Immunology at Keio University School of Medicine, were shown to be pro-inflammatory and may have a role in the onset and aggravation of IBD. The findings were recently published in Science magazine. BiomX is advancing BX002, a phage composition customized to specifically target and eradicate these IBD associated pro-inflammatory gut bacteria.

Janssen Pharmaceuticals:
In collaboration with Janssen Pharmaceuticals, Inc. we are utilizing our XMarker microbiome-based biomarker discovery platform to stratify responders and non-responders to inflammatory bowel disease (IBD) therapeutics. XMarker applies a unique metagenomics-based approach to decipher full microbial genomic signatures that can be further developed into predictive biomarkers.